Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 505

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 3
Chunk 505
---
 Accumulated other comprehensive loss 
     (575) 
     (799)
  
    Accumulated deficit 
     (163,104) 
     (121,022)
  
    TOTAL STOCKHOLDERS’ EQUITY 
     32,097  
     37,340 

    TOTAL LIABILITIES, REDEEMABLE COMMON STOCK AND STOCKHOLDERS’ EQUITY 
    $39,562  
    $57,001 

See accompanying notes to these consolidated financial
statements.

F-3

INMUNE BIO INC. 

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE
LOSS

FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023

(In
thousands, except share and per share amounts)

    2024  
    2023 
  
    REVENUE 
    $14  
    $155 

    OPERATING EXPENSES 

    General and administrative 
     9,483  
     9,623 
  
    Research and development 
     33,166  
     20,273 
  
    Total operating expenses 
     42,649  
     29,896 

    LOSS FROM OPERATIONS 
     (42,635) 
     (29,741)

    OTHER INCOME (EXPENSE), NET 

    Other income (expense), net 
     553  
     (267)
  
    Total other income (expense), net 
     553  
     (267)

    NET LOSS 
    $(42,082) 
    $(30,008)

    Net loss per common share – basic and diluted 
    $(2.11) 
    $(1.67)

    Weighted average number of common shares outstanding – basic and diluted 
     19,944,304  
     17,980,791 

    COMPREHENSIVE LOSS 

    Net loss 
    $(42,082) 
    $(30,008)
  
    Other comprehensive income (loss) – foreign currency translation 
     224  
     (100)
  
    Total comprehensive loss 
    $(41,858) 
    $(30,108)

See accompanying notes to these consolidated financial
statements. 

F-4

INMUNE BIO INC.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’
EQUITY